Valion Bio Inc (VBIO) Stock Analysis
Verdict: AVOID
Extreme cash burn and $17.4M debt force toxic preferred financing and severe dilution — the swing risk is a CDMO asset sale or BARDA contract.
Investment score: 11/100
Analysis as of
Is Valion Bio Inc stock worth reviewing? The TradeMates thesis
Valion Bio faces critical liquidity depletion and extreme equity dilution. With Q2 2026 cash of $2.11M overwhelmed by quarterly cash burn of -$5.34M and $17.41M in debt, common shareholders face severe structural downside despite biodefense asset optionality.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Valion Bio Inc opportunities and risks
What speaks for VBIO
- Government-funded non-clinical development via NIAID up to $7M for Entolimod.
What speaks against VBIO
- Critical cash runway deficiency under 1 month and $17.41M debt overhang.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| VBIO | n/a | n/a | n/a | 516.0% | 12019.2% | -1135.2% |
| VCNX | n/a | 1.0x | n/a | 98.3% | -251.1% | -321.7% |
| BRTX | n/a | 6.1x | 0.1x | 92.1% | -3089.6% | -545.2% |
| REVB | n/a | 0.0x | 0.8x | 0.0% | 0.0% | -442.3% |
| ACUT | n/a | 21.2x | n/a | 100.0% | -1680.0% | -57.7% |
| SILO | n/a | 26.1x | 0.4x | -474.3% | -8269.5% | -236.8% |
| Peer median | n/a | 6.1x | 0.1x | 92.1% | -1680.0% | -321.7% |
Frequently asked questions about Valion Bio Inc (VBIO)
Is VBIO stock a good investment?
The TradeMates model rates Valion Bio Inc as AVOID with an investment score of 11/100. Valion Bio faces critical liquidity depletion and extreme equity dilution. With Q2 2026 cash of $2.11M overwhelmed by quarterly cash burn of -$5.34M and $17.41M in debt, common shareholders face severe structural downside despite biodefense asset optionality. This is algorithmic model output, not personal investment advice.
Is VBIO stock a buy?
The TradeMates model verdict for VBIO is AVOID with an investment score of 11/100. Treat this as a model signal to review, not a personal buy recommendation.